Vital Therapies Inc Share Price Nasdaq
Equities
US92847R1041
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 110M 8.79B |
---|---|---|---|---|---|
Net income 2024 * | -93M -7.44B | Net income 2025 * | -104M -8.32B | EV / Sales 2024 * | - |
Net cash position 2024 * | 33.12M 2.65B | Net Debt 2025 * | 55.55M 4.44B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.23
x | P/E ratio 2025 * |
-1.23
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.28% |
Latest transcript on Vital Therapies Inc
Managers | Title | Age | Since |
---|---|---|---|
Daniel Vitt
CEO | Chief Executive Officer | 55 | 31/12/16 |
Glenn Whaley
DFI | Director of Finance/CFO | 56 | 30/11/19 |
Hella Kohlhof
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/12/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Barclay Phillips
BRD | Director/Board Member | 61 | 18/11/19 |
Tamar Howson
BRD | Director/Board Member | 75 | 10/10/19 |
Jörg Neermann
BRD | Director/Board Member | 57 | 31/03/19 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |